eight is something that I've thought about every single day of my adult life," says Jennifer Blackburn*, a 49-year-old public relations professional in Toronto. Following decades of trying different diets and medications-and finding little success-in fall 2022 she started taking Ozempic, the diabetes drug that has become synonymous with celebrity weight loss.
"It has been life-changing," she says.
U.S. health-care providers wrote more than 9 million prescriptions for Ozempic and similar drugs during the last few months of 2022, around the time Blackburn received her script.
Some 890 million adults have obesity worldwide, and weight-loss drug sales are forecast to grow to as much as $100 billion by the end of the decade.
No wonder obesity medications are a hot topic. But there's still mass confusion around who should take them, whether the potential side effects are worth it, and whether people who truly need them can access-and affordthe limited supply.
How do the new obesity drugs work?
Ozempic was approved by the FDA in 2017 for the treatment of type 2 diabetes.
Once the manufacturer, Novo Nordisk, tapped into the drug's added benefit of triggering substantial weight loss, it soon had another drug in the works: Wegovy, with a higher dose of the same active ingredient, semaglutide, was approved in 2021 for the treatment of obesity. The company also makes an oral form of semaglutide called Rybelsus for type 2 diabetes.
In addition to semaglutide, there is also tirzepatide, which is prescribed as Mounjaro for diabetes and Zepbound for obesity. (Again, the active ingredient is the same, but the drugs are prescribed under different names with slightly different doses.) Another diabetes drug, liraglutide, is marketed as Saxenda for weight loss. And dulaglutide is sold as Trulicity for diabetes management.
This story is from the June 2024 edition of Reader's Digest US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 2024 edition of Reader's Digest US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
A Race Well-Limped
A reluctant runner's key to keeping high spirits? Low expectations.
Won't You Be Our Neighbor?
These folks do Mr. Rogers proud
Band of Survivors
Armed with his drum kit, a Holocaust survivor fights antisemitism one musical note at a time
UMM...WHERE'S MY POOL?
All I wanted was some summer fun. What I got instead was a harsh lesson in the rip-off potential of payment apps.
Let's Say Yes!
What started out as a way to get my son to try new foods opened up a world of adventure for my family
A GRIZZLY ENCOUNTER
The bear had its jaws clamped on his friend. There was only one thing to do: tackle.
13 THINGS Go for Gold at the Olympics
THE 2024 Summer Olympic Games kick off July 26 in the host city of Paris, though several of the 41 event venues are located elsewhere in France.
STOP THE RIDE!
AMUSEMENT PARKS ARE MEANT TO THRILL. BUT OFTEN THEY JUST MAKE US SICK. ONE INTREPID RIDER IS ON A QUEST TO FIND OUT WHY SHE'S ALWAYS LOSING HER LUNCH.
Raise A GLASS!
FAVORITE DRINKS FROM EVERY STATE
A Race Well-Limped
A reluctant runner's key to keeping high spirits? Low expectations.